Apoptosis is a form of regulated cell death (RCD) that involves proteases of the caspase
family. Pharmacological and genetic strategies that experimentally inhibit or delay apoptosis …

Cancer development is driven by the accumulation of alterations affecting the structure and
function of the genome. Whereas genetic changes disrupt the DNA sequence, epigenetic …

Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …

Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

Apoptosis is a form of programmed cell death that is regulated by the balance between
prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a …

With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …

Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

PURPOSE TP53-mutated (TP53m) myelodysplastic syndromes (MDS) and acute myeloid
leukemia (AML) have very poor outcome irrespective of the treatment received, including …

Background Venetoclax combined with hypomethylating agents is a new standard of care
for newly diagnosed patients with acute myeloid leukaemia (AML) who are 75 years or …

PURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy
for relapsed/refractory FLT3-mutated (FLT3 mut) acute myeloid leukemia (AML) but seldom …